Results 41 to 50 of about 125,339 (239)

GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. [PDF]

, 2017
Although GLP-1 has been suggested as a major factor for the marked improvement of glucose tolerance commonly seen after sleeve gastrectomy (SG), several observations challenge this hypothesis.
Casamitjana i Abellà, Roser, Ferrannini, Ele, Jiménez, Amanda, Lacy Fortuny, Antonio Ma. de, Mari, Andrea, Vidal i Cortada, Josep   +5 more
core   +1 more source

Out of stock: A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 (GLP‐1) ± glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes

Journal of Diabetes
Highlights Despite the common practice of switching patients from one medicine to another—to improve efficacy, safety, or tolerability—guidance on how to do so is uncommon.
Leigh Perreault, Bryan C. Bergman
doaj   +1 more source

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective

Pharmaceuticals, 2023
Diabetes is one of the chronic metabolic disorders which poses a multitude of life-debilitating challenges, including cardiac muscle impairment, which eventually results in heart failure.
Sudhir Pandey, Supachoke Mangmool, Warisara Parichatikanond   +2 more
doaj   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle [PDF]

, 2015
Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance.
Alloosh, Mouhamad, Bell, Lauren N., Chalasani, Naga, Dineen, Stacey L., Fullenkamp, Allison M., McKenney, Mikaela L., Schultz, Kyle A., Sturek, Michael   +7 more
core   +1 more source

Copper–Collagen Interactions Regulate the Mechanical and Invasive Properties of Tumor Spheroids

Advanced Healthcare Materials, EarlyView.
Ionic copper is investigated as a modulator of tumor spheroid growth and invasiveness in a 3D microfluidic glioblastoma model. Copper exposure alters metabolic activity, cytoskeletal organization, protrusion dynamics, and EMT‐related phenotypes in a dose‐ and timing‐dependent manner, revealing how copper bioavailability shapes tumor aggressiveness ...
Paula Guerrero‐López, Jose I. Garcia‐Peiro, Felipe Hornos, Jose L. Hueso, Jesus Santamaria, J. Manuel Garcia‐Aznar   +5 more
wiley   +1 more source

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 ( [PDF]

, 2007
AIMS/HYPOTHESIS: Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes and reduced insulin secretion. The transcription factor TCF7L2 is an essential factor for glucagon-like peptide-1 (GLP-1) secretion from
S. A. Schäfer, O. Tschritter, F. Machicao, C. Thamer, N. Stefan, B. Gallwitz, J. J. Holst, J. M. Dekker, L. M. t’Hart, G. Nijpels, T. W. van Haeften, H. U. Häring, A. Fritsche, SF Grant, M Stumvoll, C Schwanstecher, GR Chandak, JV Vliet-Ostaptchouk, R Saxena, CM Damcott, C Zhang, JC Florez, LJ Scott, I Reynisdottir, S Cauchi, A Helgason, F Yi, A Fritsche, D Tripathy, LM ‘t Hart, JB Ruige, TW Haeften van, A Fritsche, M Stumvoll, O Tschritter, M Olivier, CF Deacon, M Matsuda, S Papadopoulou, L Hansen, DA D’Alessio   +40 more
core   +4 more sources

Human islets contain a subpopulation of glucagon-like peptide-1 secreting α cells that is increased in type 2 diabetes

Molecular Metabolism, 2020
Objectives: Our study shows that glucagon-like peptide-1 (GLP-1) is secreted within human islets and may play an unexpectedly important paracrine role in islet physiology and pathophysiology.
Scott A. Campbell, Dominic P. Golec, Matt Hubert, Janyne Johnson, Nicole Salamon, Amy Barr, Patrick E. MacDonald, Koenraad Philippaert, Peter E. Light   +8 more
doaj   +1 more source

Opinion: Gavage Administration of MXene as a Route‐Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post‐Transplantation Models with Bile Acid Modification

Advanced Healthcare Materials, EarlyView.
Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad, M. Akif Rahman, Ahmad Amiri   +2 more
wiley   +1 more source